Evidence map›Paper›PMID 37268618›Full record

ArticleNature communications2023

Serine ADP-ribosylation in Drosophila provides insights into the evolution of reversible ADP-ribosylation signalling.

Pietro Fontana, Sara C Buch-Larsen, Osamu Suyari, Rebecca Smith, Marcin J Suskiewicz, Kira Schützenhofer, Antonio Ariza, Johannes Gregor Matthias Rack, Michael L Nielsen, Ivan Ahel

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Pietro Fontana *Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, OX1 3RE, UK.ORCID 0000-0003-3215-3784
Sara C Buch-Larsen *Proteomics program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.ORCID 0000-0001-6250-5467
Osamu Suyari *Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, OX1 3RE, UK.ORCID 0009-0008-3258-8722
Rebecca SmithSir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, OX1 3RE, UK.ORCID 0000-0002-1658-5635
Marcin J SuskiewiczSir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, OX1 3RE, UK.ORCID 0000-0002-3279-6571
Kira SchützenhoferSir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, OX1 3RE, UK.
Antonio ArizaSir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, OX1 3RE, UK. a.ariza@sheffield.ac.uk.ORCID 0000-0003-4364-823X
Johannes Gregor Matthias RackSir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, OX1 3RE, UK. j.rack@exeter.ac.uk.ORCID 0000-0001-8341-6439
Michael L NielsenProteomics program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark. michael.lund.nielsen@cpr.ku.dk.ORCID 0000-0002-0067-9039
Ivan AhelSir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, OX1 3RE, UK. ivan.ahel@path.ox.ac.uk.ORCID 0000-0002-9446-3756
University of Oxford · GBUniversity of Copenhagen · DKBoston Children's Hospital · USCentre National de la Recherche Scientifique · FRUniversity of Exeter · GB

Funding

Biotechnology and Biological Sciences Research Council BB/R007195/1Cancer Research UK 22284Cancer Research UK C35050/A22284Medical Research Council MR/V033417/1Medical Research Council MR/X007472/1Wellcome Trust 101794Wellcome Trust 210634Wellcome Trust 210634/Z/18/Z
6 · The paper itself

Abstract

In the mammalian DNA damage response, ADP-ribosylation signalling is of crucial importance to mark sites of DNA damage as well as recruit and regulate repairs factors. Specifically, the PARP1:HPF1 complex recognises damaged DNA and catalyses the formation of serine-linked ADP-ribosylation marks (mono-Ser-ADPr), which are extended into ADP-ribose polymers (poly-Ser-ADPr) by PARP1 alone. Poly-Ser-ADPr is reversed by PARG, while the terminal mono-Ser-ADPr is removed by ARH3. Despite its significance and apparent evolutionary conservation, little is known about ADP-ribosylation signalling in non-mammalian Animalia. The presence of HPF1, but absence of ARH3, in some insect genomes, including Drosophila species, raises questions regarding the existence and reversal of serine-ADP-ribosylation in these species. Here we show by quantitative proteomics that Ser-ADPr is the major form of ADP-ribosylation in the DNA damage response of Drosophila melanogaster and is dependent on the dParp1:dHpf1 complex. Moreover, our structural and biochemical investigations uncover the mechanism of mono-Ser-ADPr removal by Drosophila Parg. Collectively, our data reveal PARP:HPF1-mediated Ser-ADPr as a defining feature of the DDR in Animalia. The striking conservation within this kingdom suggests that organisms that carry only a core set of ADP-ribosyl metabolising enzymes, such as Drosophila, are valuable model organisms to study the physiological role of Ser-ADPr signalling.

Indexed as

DrosophilaSerineAdenosine Diphosphate RiboseADP-RibosylationAnimalsDrosophila melanogasterMammalsPoly Adenosine Diphosphate RiboseAdenosine Diphosphate RibosePoly Adenosine Diphosphate RiboseSerine

Identifiers

PMID37268618
PMCPMC10238386
OpenAlexW4379141402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.